Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433114 | 1.00 | HTR2A (0.45) | HTR2AHTR2CHTR2BKDM4ETSHR | |
| SCHEMBL6081106 | 0.83 | CHRM2 (0.39) | KDM4EHTR7CHRM4CHRM1 | |
| SCHEMBL30704762 | 0.82 | PSEN1 (0.35) | — | |
| SCHEMBL28474977 | 0.82 | PSEN1 (0.35) | — | |
| SCHEMBL23327793 | 0.76 | HTR2A (0.43) | HTR2AHTR2CHTR2BKDM4ETSHR | |
| SCHEMBL10985710 | 0.72 | CYP3A4 (0.42) | KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL2482801 | 0.72 | MAOB (0.39) | — | |
| SCHEMBL2481090 | 0.72 | MAOB (0.39) | — | |
| SCHEMBL31371272 | 0.71 | KDM1A (0.45) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL20859649 | 0.71 | KDM1A (0.45) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-111971287-A | Macrocyclic compounds as TRK kinase inhibitors | 重庆复创医药研究有限公司 | 2020-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | PLK2, ERBB3, DMPK | HTR2A 2430/4885HTR2C 1867/4885HTR2B 2809/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | HTR2A 2430/4885HTR2C 1867/4885HTR2B 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.